Camlin Fine Sciences Releases Investor Presentation for Q4 & FY26 Results
Camlin Fine Sciences released its investor presentation for Q4 & FY26 results. Revenue for Q4 FY26 was ₹4,248 million and ₹17,233 million for FY26. Blends business grew 17% annually, with Vinpai contributing ₹165 million. EBITDA was ₹212 million with a 5.0% margin. Improved Vanillin realisations and volumes are expected.
The announcement provides detailed financial results and performance highlights, which are crucial for investors to assess the company's current standing and future prospects. The inclusion of segment-wise performance, regional highlights, and future outlook makes it a significant update for stakeholders.
The announcement is an investor presentation of financial results. While it provides performance data, it also highlights challenges like regional conflict impacting sales and raw material costs, alongside positive outlooks for specific business segments. The overall sentiment is neutral as it balances positive and negative factors.
Camlin Fine Sciences Limited has released its investor presentation for the audited financial results for the quarter and year ended March 31, 2026. This follows their earlier disclosure on May 20, 2026, regarding a conference call to discuss these results.
The presentation provides a detailed overview of the company's financial performance, including revenue, EBITDA, and PAT figures for Q4 FY26 and the full fiscal year FY26, presented on a consolidated basis. Revenue for Q4 FY26 stood at ₹4,248 million and ₹17,233 million for FY26. The company noted that the conflict in the region had an adverse impact on sales in March 2026, affecting raw material availability, logistics costs, and working capital cycles. Pricing pressures on Straights due to local competition also impacted profitability.
The Blends business showed steady growth with an annual growth of 17%, and the newly acquired Vinpai contributed ₹165 million to the Blends revenue in Q4 FY26. Lower production of Methyl Vanillin in Q4 FY26 was due to a planned campaign switch for Ethyl Vanillin, with internal channel stock of Vanillin being liquidated. Higher realisations for Vanillin are expected in subsequent quarters due to tariff withdrawal.
EBITDA for the quarter was ₹212 million, with a margin of 5.0%. Rising interest costs and currency fluctuations impacted profitability. CFS Europe is under liquidation, which is expected to curtail its operational losses. The outlook for the next financial year is positive, with expectations of improved Vanillin realisations and volumes, and continued growth momentum for Blends. However, lingering conflict situations might hamper growth in the first part of FY2027. The presentation also detailed revenue breakups by product category and region, as well as a consolidated profit and loss statement and balance sheet.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.